



## Seventure Partners Invests in Liver Diagnosis Specialist Humedics

### *EUR 6.3 million financing round for commercialization of the LiMAx test*

**Paris, France, November 10, 2014** – Seventure Partners, one of Europe’s leaders in financing innovation, announces today its first investment in the Germany based company Humedics, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient.

The series C financing round of more than EUR 6.3 million was led by Seventure Partners and Vesalius Biocapital Partners, two new international investors, and joined by all venture capital investors from previous rounds.

The raised capital will be used to support the European market entry of Humedics’ proprietary LiMAx breath test and the corresponding FLIP diagnostic device. This breath test-based diagnostic system is a major step forward in functional liver diagnostics. Clinicians will be able to quantitatively determine the individual liver function capacity for a patient within minutes. The test allows for better risk assessment of patients in liver surgery and thus, superior surgery planning as well as selecting treatment strategies optimally adapted to the individual patient’s liver status. The LiMAx test provides certainty for the physician, safety for the patient and leads to cost reduction for the hospital.

The existing syndicate includes Peppermint VenturePartners (managing the Charité Biomedical Fund), VC Fonds Technologie managed by IBB-Beteiligungsgesellschaft, ERP Startfonds of the Kreditanstalt für Wiederaufbau (KfW), Ventegis and High-Tech Gründerfonds. Dr. Robert Schier from Seventure Partners and Vesalius Managing Partner Dr. Christian Schneider will join the Humedics Board, reinforcing the current board that consists of Dr. Klaus Stöckemann (Peppermint VenturePartners), Ute Mercker (IBB Beteiligungsgesellschaft) and Dr. Volker Pfahlert (Numares Group).

Isabelle de Cremoux, CEO and Managing Partner at Seventure Partners, said: “The LiMAx test can make a major contribution to optimizing the treatment of patients with acute and chronic liver failure, and it has the potential to become a gold standard in liver diagnostics. Seventure has joined this consortium of investors to support Humedics during the application procedure for its marketing authorization in 2015 and subsequent commercialization.”

-ENDS-

#### Contact:

At Seventure Partners:	For media enquiries (Instinctif Partners):
Isabelle de Cremoux CEO/Managing Partner Tel: +33 6 77 05 4992 Email: <a href="mailto:isabelle.decremoux@seventure.fr">isabelle.decremoux@seventure.fr</a>	Melanie Toyne Sewell Robert Mayer Tel: +44 20 7866 7860 Email: <a href="mailto:seventure@instinctif.com">seventure@instinctif.com</a>

#### Notes to Editors

##### About Seventure Partners

Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure has invested in innovative businesses with high growth potential in digital technologies in France and Germany and in the life sciences field across Europe, with currently over €500m in assets under management.

In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology and cleantech, and last but not least: the microbiome, nutrition, personalized medicine and

food. Seventure Partners also considers investments in the field of diagnostics, biomarkers, drug delivery systems, lifestyle healthcare and services.

Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage.

In December 2013, Seventure Partners successfully launched its 'Health for Life Capital' Fund which attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis, the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more information, please visit: [www.seventure.com](http://www.seventure.com)

### **About Humedics**

Humedics has developed a breath test based diagnostic system (LiMAx test), which comprises a CE- marked medical device, breath masks and a diagnostic drug. More than 100 million people world-wide suffer from liver diseases (i.e. cirrhosis, hepatitis, fatty liver, metabolic disorders and liver tumors). The LiMAx test enables the clinician to quantitatively determine the individual liver function capacity for a patient within minutes. This allows for selection of treatment strategies that are optimally adapted to the individual patients liver status. Current applications include diagnosis of the liver function before and after liver transplantation, liver surgery planning (e.g. assessment of the amount of liver to be resected without potentially increasing the risk of liver failure) and assessment of diseases such as liver cirrhosis. The LiMAx test has been used more than 12,500 times in clinical practice. Results have been published in highly respected scientific journals. For the approval of the LiMAx test Humedics is presently conducting a phase III multi-center clinical trial. Results are expected mid 2015.

### **LiMAx Test**

The underlying principle of the LiMAx test involves the following steps: Firstly, the diagnostic drug solution is administered intravenously and the drug is metabolized in the liver to paracetamol and  $^{13}\text{CO}_2$ . The latter is exhaled in the breath. The exhaled air is collected via a respiratory mask. Subsequent continuous measurement of  $^{13}\text{CO}_2$  in the patients' breath using laser detection in the FLIP device provides a quantitative determination of the liver capacity and thus reflects the liver function.